Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 855

-Electricity of Life💡: Wonders of Bioelectricity and Regenerative Biology Prof Michael Levin

Welcome to another exciting episode of our podcast series, where we dive deep into the world of science and innovation! In today’s episode, we have the privilege of interviewing Prof. Michael Levin, a renowned researcher in the fields of bioelectricity, regenerative biology, and biophysics.

Prof. Levin is the director of the Allen Discovery Center at Tufts University and has been making groundbreaking discoveries that are revolutionizing the field of regenerative medicine. His research focuses on understanding the electrical communication within and between cells, and how this communication can be harnessed for tissue repair and regeneration.

In this thought-provoking conversation, we cover:

đŸ”č The fundamentals of bioelectricity and its role in cellular communication.
đŸ”č How bioelectric signals can be manipulated to control cell behavior.
đŸ”č Prof. Levin’s pioneering work in regenerative medicine and tissue engineering.
đŸ”č The potential applications of bioelectricity in treating various diseases and conditions.
đŸ”č Ethical considerations and the future of bioelectricity in healthcare.

Join us for this insightful discussion and learn how Prof. Levin’s research is paving the way for innovative solutions in regenerative medicine. Don’t forget to subscribe to our channel for more fascinating interviews with leading experts in science and technology!

Restoring A Person’s Voice Using A Brain-Computer Interface

Being able to vocalize is one of the most essential elements of the human experience, with infants expected to start babbling their first words before they’re one year old, and much of their further life revolving around interacting with others using vocalizations involving varying degrees of vocabulary and fluency. This makes the impairment or loss of this ability difficult to devastating, as is the case with locked-in syndrome (LIS), amyotrophic lateral sclerosis (ALS) and similar conditions, where talking and vocalizing has or will become impossible.

In a number of concurrent studies, the use of a brain-computer interface (BCI) is investigated to help patients suffering from LIS (Sean L. Metzger et al., 2023) and ALS (Francis R. Willett et al., 2023) to regain their speaking voice. Using the surgically implanted microelectrode arrays (Utah arrays) electrical impulses pertaining to the patient’s muscles involved in speaking are recorded and mapped to phonemes, which are the elements that make up speech. Each of these phonemes requires a specific configuration of the muscles of the vocal tract (e.g. lips, tongue, jaw and larynx), which can be measured with a fair degree of accuracy.

In the case of the study by Sean L. Metzger et al. as recently published in Nature, the accompanying research article on the University of California San Francisco website details the story of their patient: Ann. At the age of 30, Ann suffered a brainstem stroke which rendered her essentially fully paralyzed. As an LIS patient she lacked for a long time even the ability to move her facial muscles.

Innovative insights into effects of hematopoietic changes on colon cancer, unveiling therapeutic avenues

In a recent study published in the Journal of Experimental Medicine, researchers investigated whether bone marrow-derived cells with heterozygous loss of Dnmt3a (Dnmt3a+/Δ), the most common genetic alteration in clonal hematopoiesis (CH), contribute to colitis-associated colon cancer (CAC) pathogenesis.

Study: Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer. Image Credit: vetpathologist/Shutterstock.com.

Promising New Cancer Drug May Kill Cancer Cells with Minimal Side Effects

An exciting new cancer drug has recently entered into a phase 1 clinical trial supported by promising pre-clinical work. The drug, named AOH1996, targets a protein called proliferating cell nuclear antigen (PCNA), an essential player in the biological processes of DNA replication and repair. A team of researchers from City of Hope published the data describing how they identified and characterized AOH1996 in Cell Chemical Biology last week. Since then, the news of AOH1996 has appeared prominently in both scientific and mainstream media.

Using a rational drug design approach that develops drugs based on their specific biological targets, the researchers identified AOH1996. Lead researcher Linda Malkas named the drug after Anna Oliva Healey, a girl born in 1996 who succumbed to neuroblastoma at age 9.

In the laboratory, the researchers tested AOH1996 on over 70 different kinds of tumor cells as well as some healthy control cells. While the drug killed the cancer cells, it notably does not affect non-cancer cells, including blood cells and the cells lining the airway. This indicates AOH1996 as a selective drug that will suppress tumor growth but likely not cause adverse effects that can occur when a cancer drug damages healthy cells.

New tech is step towards lab-grown blood vessels

Innovative technology that creates ultra-thin layers of human cells in tube-like structures could spur development of lifelike blood vessels and intestines in the lab.

The technique, known as RIFLE – rotational internal flow layer engineering – enables the construction of separate layers as delicate as one cell thick.

Such versatility is crucial to developing accurate human models of layered tubular tissue for use in research, offering an important alternative to animal models, experts say.

Harvard/MIT Scientists Claim New “Chemical Cocktails” Can Reverse Aging

That’s why we were struck to see a team of scientists that includes researchers from the name-brand Harvard Medical School and Massachusetts Institute of Technology sounding off about what they say are promising new leads, published this month in the journal Aging.

“We identify six chemical cocktails, which, in less than a week and without compromising cellular identity, restore a youthful genome-wide transcript profile and reverse transcriptomic age,” reads the paper. “Thus, rejuvenation by age reversal can be achieved, not only by genetic, but also chemical means.”

Sounds big, right? The researchers claim they pinpointed six treatments that can reverse aging in cells and turn them into a more “youthful state,” according to a press release from Aging’s publisher, without causing dangerous unregulated cell growth.

Bacteria treatment reduces insulin resistance, protects against diabetes

Researchers led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have discovered a type of gut bacteria that might help improve insulin resistance, and thus protect against the development of obesity and type-2 diabetes. The study, published August 30 in the scientific journal Nature, involved genetic and metabolic analysis of human fecal microbiomes and then corroborating experiments in obese mice.

Insulin is a hormone released by the pancreas in response to blood sugar. Normally, it helps get the sugar into the muscles and liver so that they can use the energy. When someone develops insulin resistance, it means that insulin is prevented from doing its job, and as a result, more sugar stays in their blood and their pancreas continues to make more insulin. Insulin resistance can lead to obesity, pre-diabetes, and full-blown type-2 diabetes.

Our guts contain trillions of bacteria, many of which break down the carbohydrates that we eat when they would otherwise remain undigested. While many have proposed that this phenomenon is related to obesity and pre-diabetes, the facts remain unclear because there are so many different bacteria and there is a lack of metabolic data. Ohno and his team at RIKEN IMS have addressed this lack with their comprehensive study, and in the process, discovered a type of bacteria that might help reduce insulin resistance.

Single-Incision Laparoscopic Surgery effective for Gastrointestinal Stromal Tumor

In a recent study, Ji Won Seo and team found the outcomes of single-incision laparoscopic surgery (SILS) better than conventional laparoscopic surgery (CLS) for treating gastric gastrointestinal stromal tumors (GISTs). The findings of the study were published in BMC Surgery.

Between November 2020 and April 2022, a group of 15 consecutive patients with gastric GIST underwent single-incision gastric wedge resection, forming the SILS group. This group’s early perioperative outcomes were then meticulously analyzed and compared with a corresponding group of 15 patients who had undergone conventional laparoscopic surgery (CLS). The selection criteria for the surgical approach were consistent with those used for traditional laparoscopic procedures for gastric GIST.

The study’s findings revealed several significant insights. The estimated blood loss and intraoperative blood transfusion were comparable between the SILS and CLS groups, signifying similar surgical efficacy and safety. Notably, the SILS group experienced no intraoperative complications or instances requiring a shift to multiple-port or open surgery.